Context Therapeutics Inc. Common Stock

CNTXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
2.38 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
2.39
↗ 0.01 (0.38%)
POST MARKET (AS OF 07:23 PM EDT)
Post Market
AS OF 07:23 PM EDT
2.39
↗ 0.01 (0.38%)
🔴Market: CLOSED
Open?$2.33
High?$2.40
Low?$2.27
Prev. Close?$2.38
Volume?537.7K
Avg. Volume?827.6K
VWAP?$2.34
Rel. Volume?0.65x
Bid / Ask
Bid?$2.01 × 100
Ask?$2.76 × 100
Spread?$0.75
Midpoint?$2.39
Valuation & Ratios
Market Cap?218.7M
Shares Out?91.9M
Float?67.5M
Float %?73.5%
P/E Ratio?N/A
P/B Ratio?4.19
EPS?-$0.44
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
15
Market Cap
218.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.contexttherapeutics.com
Listed
2021-10-20
Address
2001 MARKET STREET
PHILADELPHIA, PA 19103
Phone: 267-225-7416
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?8.96Strong
Quick Ratio?8.96Strong
Cash Ratio?8.34Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
83/100
P/E?
N/A▾
P/B?
4.19FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
-3.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
-77.1%WEAK▾
ROA?
-68.3%WEAK▾
Cash Flow & Enterprise
FCF?$-32823631
Enterprise Value?$164.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist